154 related articles for article (PubMed ID: 34868998)
1. Two Novel Ceramide-Like Molecules and miR-5100 Levels as Biomarkers Improve Prediction of Prostate Cancer in Gray-Zone PSA.
Mello-Grand M; Bruno A; Sacchetto L; Cristoni S; Gregnanin I; Dematteis A; Zitella A; Gontero P; Peraldo-Neia C; Ricotta R; Noonan DM; Albini A; Chiorino G
Front Oncol; 2021; 11():769158. PubMed ID: 34868998
[TBL] [Abstract][Full Text] [Related]
2. Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone.
Salido-Guadarrama AI; Morales-Montor JG; Rangel-Escareño C; Langley E; Peralta-Zaragoza O; Cruz Colin JL; Rodriguez-Dorantes M
Mol Med Rep; 2016 Jun; 13(6):4549-60. PubMed ID: 27081843
[TBL] [Abstract][Full Text] [Related]
3. Metabolomics Profiling Discriminates Prostate Cancer From Benign Prostatic Hyperplasia Within the Prostate-Specific Antigen Gray Zone.
Xu B; Chen Y; Chen X; Gan L; Zhang Y; Feng J; Yu L
Front Oncol; 2021; 11():730638. PubMed ID: 34722271
[TBL] [Abstract][Full Text] [Related]
4. Different levels of serum microRNAs in prostate cancer and benign prostatic hyperplasia: evaluation of potential diagnostic and prognostic role.
Cochetti G; Poli G; Guelfi G; Boni A; Egidi MG; Mearini E
Onco Targets Ther; 2016; 9():7545-7553. PubMed ID: 28008272
[TBL] [Abstract][Full Text] [Related]
5. Blood-based microRNAs as diagnostic biomarkers to discriminate localized prostate cancer from benign prostatic hyperplasia and allow cancer-risk stratification.
Al-Kafaji G; Said HM; Alam MA; Al Naieb ZT
Oncol Lett; 2018 Jul; 16(1):1357-1365. PubMed ID: 30061955
[TBL] [Abstract][Full Text] [Related]
6. Circulating microRNAs combined with PSA for accurate and non-invasive prostate cancer detection.
Mello-Grand M; Gregnanin I; Sacchetto L; Ostano P; Zitella A; Bottoni G; Oderda M; Marra G; Munegato S; Pardini B; Naccarati A; Gasparini M; Gontero P; Chiorino G
Carcinogenesis; 2019 Apr; 40(2):246-253. PubMed ID: 30452625
[TBL] [Abstract][Full Text] [Related]
7. Identification of microRNAs differentially expressed in prostatic secretions of patients with prostate cancer.
Guzel E; Karatas OF; Semercioz A; Ekici S; Aykan S; Yentur S; Creighton CJ; Ittmann M; Ozen M
Int J Cancer; 2015 Feb; 136(4):875-9. PubMed ID: 24976077
[TBL] [Abstract][Full Text] [Related]
8. MiR-182-5p and miR-375-3p Have Higher Performance Than PSA in Discriminating Prostate Cancer from Benign Prostate Hyperplasia.
Abramovic I; Vrhovec B; Skara L; Vrtaric A; Nikolac Gabaj N; Kulis T; Stimac G; Ljiljak D; Ruzic B; Kastelan Z; Kruslin B; Bulic-Jakus F; Ulamec M; Katusic-Bojanac A; Sincic N
Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33922968
[TBL] [Abstract][Full Text] [Related]
9. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL.
Kwiatkowski MK; Recker F; Piironen T; Pettersson K; Otto T; Wernli M; Tscholl R
Urology; 1998 Sep; 52(3):360-5. PubMed ID: 9730444
[TBL] [Abstract][Full Text] [Related]
10. Semen miRNAs Contained in Exosomes as Non-Invasive Biomarkers for Prostate Cancer Diagnosis.
Barceló M; Castells M; Bassas L; Vigués F; Larriba S
Sci Rep; 2019 Sep; 9(1):13772. PubMed ID: 31551516
[TBL] [Abstract][Full Text] [Related]
11. Circulating let-7f-5p improve risk prediction of prostate cancer in patients with benign prostatic hyperplasia.
Ge Y; Wang Q; Shao W; Zhao Y; Shi Q; Yuan Q; Cui L
J Cancer; 2020; 11(15):4542-4549. PubMed ID: 32489471
[No Abstract] [Full Text] [Related]
12. Analysis of circulating miRNAs 21 and 375 as potential biomarkers for early diagnosis of prostate cancer.
Gao Y; Guo Y; Wang Z; Dai Z; Xu Y; Zhang W; Liu Z; Li S
Neoplasma; 2016; 63(4):623-8. PubMed ID: 27268927
[TBL] [Abstract][Full Text] [Related]
13. Urinary MicroRNAs of Prostate Cancer: Virus-Encoded hsv1-miRH18 and hsv2-miR-H9-5p Could Be Valuable Diagnostic Markers.
Yun SJ; Jeong P; Kang HW; Kim YH; Kim EA; Yan C; Choi YK; Kim D; Kim JM; Kim SK; Kim SY; Kim ST; Kim WT; Lee OJ; Koh GY; Moon SK; Kim IY; Kim J; Choi YH; Kim WJ
Int Neurourol J; 2015 Jun; 19(2):74-84. PubMed ID: 26126436
[TBL] [Abstract][Full Text] [Related]
14. A novel urinary mRNA signature using the droplet digital polymerase chain reaction platform improves discrimination between prostate cancer and benign prostatic hyperplasia within the prostate-specific antigen gray zone.
Kang HW; Lee HY; Byun YJ; Jeong P; Yoon JS; Kim DH; Kim WT; Kim YJ; Lee SC; Yun SJ; Kim WJ
Investig Clin Urol; 2020 Jul; 61(4):411-418. PubMed ID: 32665998
[TBL] [Abstract][Full Text] [Related]
15. Differential blood-based diagnosis between benign prostatic hyperplasia and prostate cancer: miRNA as source for biomarkers independent of PSA level, Gleason score, or TNM status.
Leidinger P; Hart M; Backes C; Rheinheimer S; Keck B; Wullich B; Keller A; Meese E
Tumour Biol; 2016 Aug; 37(8):10177-85. PubMed ID: 26831660
[TBL] [Abstract][Full Text] [Related]
16. MiR-145 detection in urinary extracellular vesicles increase diagnostic efficiency of prostate cancer based on hydrostatic filtration dialysis method.
Xu Y; Qin S; An T; Tang Y; Huang Y; Zheng L
Prostate; 2017 Jul; 77(10):1167-1175. PubMed ID: 28617988
[TBL] [Abstract][Full Text] [Related]
17. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS
Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
[TBL] [Abstract][Full Text] [Related]
18. Profiling of Circulating microRNAs in Prostate Cancer Reveals Diagnostic Biomarker Potential.
Fredsøe J; Rasmussen AKI; Mouritzen P; Bjerre MT; Østergren P; Fode M; Borre M; Sørensen KD
Diagnostics (Basel); 2020 Mar; 10(4):. PubMed ID: 32231021
[TBL] [Abstract][Full Text] [Related]
19. Is prostate volume better than PSA density and free/total PSA ratio in predicting prostate cancer in patients with PSA 2.5-10 ng/mL and 10.1-30 ng/mL?
Erdogan A; Polat S; Keskin E; Turan A
Aging Male; 2020 Mar; 23(1):59-65. PubMed ID: 30862227
[No Abstract] [Full Text] [Related]
20. Identification of Multisialylated LacdiNAc Structures as Highly Prostate Cancer Specific Glycan Signatures on PSA.
Haga Y; Uemura M; Baba S; Inamura K; Takeuchi K; Nonomura N; Ueda K
Anal Chem; 2019 Feb; 91(3):2247-2254. PubMed ID: 30669833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]